Developing vaccines to protect against Ebola and Marburg viruses
Official title: Advanced Development of Vaccines for Filoviruses
Funded at Auro Vaccines LLC · NIH-11083538 · Data updated 2026-11-12
This study is working on a new vaccine that aims to protect people from several serious viruses, like Ebola and Marburg, as well as Lassa Fever, making it easier to store and distribute, so that one day, patients can have better protection against these infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auro Vaccines LLC NIH-funded |
| Lab location | 1 site (East Windsor, United States) |
| Project start | July 21, 2020 |
| Project end | December 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,033,940 |
| NIH project number | 75N93020C00040-P00010-9999-1 |
| Project ID | NIH-11083538 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at high risk of exposure to filoviruses, such as healthcare workers or those living in endemic regions.
✕Less likely to help
Patients who are not at risk of exposure to these viruses or who have already been vaccinated against them may not benefit from this research.
What this research studies
This research focuses on creating a multivalent vaccine that can protect against multiple filoviruses, including Ebola and Marburg viruses, as well as Lassa Fever. The approach involves formulating a stable vaccine that can be lyophilized for easier storage and distribution. The project will also support the manufacturing process under current Good Manufacturing Practices (cGMP) and prepare for clinical evaluation by submitting an Investigational New Drug (IND) application. Patients may eventually benefit from a vaccine that provides broader protection against these serious viral infections.
Why it matters
Potential benefit: If successful, this research could lead to a vaccine that significantly reduces the risk of infection from Ebola, Marburg, and Lassa viruses.
How similar studies have gone: Previous research has shown promise in developing vaccines for filoviruses, indicating that this approach has potential for success.
Where this research is happening
-
Auro Vaccines LLC
East Windsor, United States Active
Researchers
- Principal investigator: Eldridge, John — Auro Vaccines LLC
- Study coordinator: Eldridge, John
Related research
Other NIH-funded projects on the same topics.
-
Developing vaccines to protect against Ebola and related viruses
This study is working on a new vaccine that could help protect people from several serious viruses like Ebola, Marburg, and Lassa Fever, making it easier to store and distribute, so it can be tested in the future to keep everyone safer.
-
Developing vaccines to protect against Ebola and related viruses
This study is working on a new vaccine that aims to protect people from several serious viruses, like Ebola and Marburg, and it hopes to make it easier to store and distribute, so that one day, patients can have better protection against these infections.
-
Developing vaccines to protect against Ebola and related viruses
This study is working on a new vaccine that could help protect people from serious viruses like Ebola, Marburg, and Lassa Fever, making it easier to store and transport so it can be used to keep everyone safe in the future.
-
Developing vaccines to protect against Ebola and related viruses
This study is working on a new vaccine that could help protect people from several serious viruses like Ebola, Marburg, and Lassa Fever, and it’s designed to be easy to store and use, making it safer and more accessible for everyone.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.